Aurora Cannabis (ACB) is pleased to announce the company’s discovery of a novel source of genetic resistance against powdery mildew, PM2, that provides strong protection against this pathogen in cannabis sativa. The development of this proprietary genetic marker technology, which is now in use in Aurora’s breeding program, is set to produce powdery mildew resistant cultivars that will be explored for commercial launch this year.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACB:
- Aurora Cannabis expands medical cannabis pastille offerings in Australia
- Aurora Cannabis Enhances Access to Medical Cannabis in Australia
- Aurora Cannabis (ACB) Trades at a Discount Despite Record-Breaking Quarter
- Aurora Cannabis Secures Strategic $27 Million Supply Agreement with SNDL
- Aurora Cannabis announces supply agreement with SNDL